BB Biotech AG (BBZA)

Profile

https://www.bbbiotech.ch/en/bb-biotech/

BB Biotech AG is a Switzerland-based investment company specializing in the biotechnology sector. Founded in 1993 and headquartered in Schaffhausen, it invests primarily in publicly traded companies developing and commercializing innovative drugs that address significant unmet medical needs, such as oncology, infectious diseases, neurological disorders, metabolic and cardiovascular conditions, and autoimmune diseases. The portfolio typically comprises 20 to 35 companies, with a focus on small- to mid-cap firms in the United States and Western Europe, alongside established large-cap players, emphasizing technologies like RNA platforms, cell, and gene therapies. Managed by Bellevue Asset Management AG, BB Biotech employs a bottom-up fundamental analysis approach, targeting firms with promising R&D pipelines, advanced drug candidates, and strong leadership to drive healthcare value and efficiency. As one of the world's largest biotech investors with over 30 years of experience, it operates through subsidiaries like Biotech Invest NV and provides investors access to this dynamic, double-digit growth sector fueled by trends in life expectancy and healthcare innovation. The board, chaired by Thomas von Planta, oversees strategy, supported by a team led by Christian Koch. With around 10 employees, BB Biotech plays a pivotal role in channeling capital to biotech advancements enhancing global health and well-being.